Clinical Trials for Small Cell Lung Cancer

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with selected histiocytic neoplasms, higher-risk MDS, CMML, primary myelofibrosis, or specified lymphomas or CLL/SLL who generally have relapsed or refractory disease or limited standard treatment options receive oral Q702 (adrixetinib) alone. Q702 is an investigational AXL, MER, and CSF1R inhibitor given intermittently in 28-day cycles.

ClinicalTrials.gov ID: NCT06712810

A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and selected advanced or metastatic solid tumors receive AZD6750, an investigational CD8-guided IL-2 agent designed to preferentially stimulate CD8-positive T cells. A separate cohort of patients with stage IV NSCLC receives AZD6750 plus rilvegostomig, an investigational PD-1/TIGIT bispecific antibody.

ClinicalTrials.gov ID: NCT07115043

A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination With Atezolizumab With or Without Carboplatin as First-line Induction or Maintenance, in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with extensive-stage small-cell lung cancer and ECOG performance status 0–1 receive ifinatamab deruxtecan plus atezolizumab either as maintenance after responding to or remaining stable on first-line carboplatin, etoposide, and atezolizumab, or with carboplatin as initial treatment followed by maintenance. Ifinatamab deruxtecan is an investigational B7-H3–targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT06362252

An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls adults with extensive-stage or metastatic SCLC, including previously treated patients, treatment-naive patients, and patients with disease control after first-line therapy, depending on the cohort. It evaluates the DLL3-targeting antibody–drug conjugate ZL-1310, which delivers a topoisomerase I inhibitor, alone or with atezolizumab, with some cohorts also receiving carboplatin induction.

ClinicalTrials.gov ID: NCT06179069

A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For patients with stage IV small cell lung cancer that has relapsed or progressed after at least one platinum-containing regimen, this study evaluates gocatamig (MK-6070), a DLL3/CD3-targeting T-cell engager, and ifinatamab deruxtecan, a B7-H3–targeting antibody–drug conjugate carrying a topoisomerase I inhibitor, alone or together. Another arm evaluates gocatamig plus the PD-L1 inhibitor durvalumab.

ClinicalTrials.gov ID: NCT06780137

A Phase 1 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Patients With Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with DLL3-positive small cell lung cancer who have failed or cannot tolerate standard treatment and have ECOG performance status 0–1 receive escalating doses of alveltamig (ZG006). This investigational antibody engages CD3-positive T cells and binds DLL3 on tumor cells to promote tumor-cell killing.

ClinicalTrials.gov ID: NCT06592638

Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with progressive, metastatic or inoperable gastrointestinal neuroendocrine tumors, pheochromocytoma/paraganglioma, small cell lung cancer, primary kidney cancer, or selected head and neck cancers are eligible if at least half of their measurable tumor shows somatostatin-receptor uptake on PET. Patients receive intravenous [212Pb]VMT-alpha-NET, a somatostatin-receptor–targeted radioligand that delivers alpha-particle radiation, every 8 weeks for four doses; a subset also receives [203Pb]VMT-alpha-NET for dosimetry.

ClinicalTrials.gov ID: NCT06479811

A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined With Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with extensive-stage SCLC and response or stable disease after 4–6 cycles of platinum–etoposide plus atezolizumab or durvalumab receive maintenance checkpoint inhibition alone or with oral iadademstat, an LSD1 (KDM1A) inhibitor.

ClinicalTrials.gov ID: NCT06287775

A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors that have progressed after at least one systemic therapy receive FT836, an off-the-shelf, induced pluripotent stem cell–derived CAR T-cell therapy targeting MICA/MICB. FT836 is given alone or with paclitaxel, cetuximab, or trastuzumab, including paclitaxel–antibody combinations.

ClinicalTrials.gov ID: NCT07216105

A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or recurrent NSCLC and ECOG 0–1 are eligible for cohorts spanning previously treated disease, including EGFR-mutant disease after EGFR inhibitors, and untreated disease without actionable alterations. Treatment centers on BNT326, a HER3-directed antibody–drug conjugate delivering a topoisomerase-I inhibitor, plus BNT327, a PD-L1/VEGF-A bispecific antibody; selected cohorts also evaluate either drug alone or compare the combination with first-line pembrolizumab-based treatment.

ClinicalTrials.gov ID: NCT07111520